AGS-003: Additional Phase II data

Additional data from an ongoing, open-label Phase II trial in 22 newly diagnosed patients who have undergone nephrectomy showed that intradermal AGS-003 every 3 weeks plus Sutent sunitinib led to a median PFS of 14.9 months in intermediate-risk patients and 6 months in poor-risk patients. Argos said the data compare favorably to historical results of 10.6 and 3.7 months for intermediate- and poor-risk patients, respectively, for Sutent alone. Data were presented at the International Kidney Cancer meeting in Chicago. ...